ReviewCurrent oncology reports2007
Diagnosis and treatment of acute promyelocytic leukemia.
Review in Current oncology reports, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- CD1d expression in glioblastoma is a promising target for NKT cell-based cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2021Article
- Review
- Article
- Article
- IRES inhibition induces terminal differentiation and synchronized death in triple-negative breast cancer and glioblastoma cells.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- NPM and BRG1 Mediate Transcriptional Resistance to Retinoic Acid in Acute Promyelocytic Leukemia.Cell reports · 2016Article
- Molecular characteristics of cancer stem-like cells derived from human breast cancer cells.Anticancer research · 2013Article
- Bradycardia following retinoic acid differentiation syndrome in a patient with acute promyelocytic leukaemia.BMJ case reports · 2012Article
- Emerging new approaches for the treatment of acute promyelocytic leukemia.Therapeutic advances in hematology · 2011Article
- Regulation of glioblastoma stem cells by retinoic acid: role for Notch pathway inhibition.Oncogene · 2011Article
- Article
- PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice.The Journal of clinical investigation · 2011Article
- Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice.Blood · 2011Article
- Allium compounds, dipropyl and dimethyl thiosulfinates as antiproliferative and differentiating agents of human acute myeloid leukemia cell lines.Biologics : targets & therapy · 2008Article
- Old drugs--new uses.British journal of clinical pharmacology · 2007Article
- Development of Flow Cytometry-Fluorescent In Situ Hybridization (Flow-FISH) Method for Detection of PML/RARa Chromosomal Translocation in Acute Promyelocytic Leukemia Cell Line.Avicenna journal of medical biotechnologyArticle
- Classic and molecular cytogenetic findings in leukemia patients from the Western part of Romania.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute promyelocytic leukemia (APL), characterized by a translocation between the promyelocytic leukemia gene (PML) on chromosome 15 and the retinoic acid receptor-alpha (RARalpha) gene on chromosome 17, has become a model for targeted treatment of cancer. Advances in our understanding of the fundamental biology of this disease have led to the development of tools for diagnosis, monitoring of minimal residual disease, and detection of early relapse. Differentiation therapy with all-trans retinoic acid in combination with chemotherapy has significantly improved survival in patients with APL. Moreover, arsenic trioxide, which induces differentiation and apoptosis of APL cells, has become standard treatment for relapsed disease, and its role in the treatment of newly diagnosed APL is under active investigation. The lessons learned from APL have broad applications to other forms of leukemia and to cancer in general, whereby molecularly targeted therapy is directed to specifically defined subgroups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.